Evidence map›Paper›PMID 41989657›Full record

ArticleDermatology and therapy2026

How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach.

Brett King, Maryanne Senna, Manabu Ohyama, Rodney Sinclair, Najwa Somani, Na Lu, Yun-Fei Chen, Jakub Jedynak, Andrew Buchanan, Bianca Maria Piraccini

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03570749 phase2 / phase3completednot on this map

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata

TypeinterventionalSponsorEli Lilly and CompanyRan2018 to 2025Enrolled784ConditionsAlopecia AreataArmsBaricitinib, Placebo
NCT03899259 phase3completednot on this map

A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata

TypeinterventionalSponsorEli Lilly and CompanyRan2019 to 2024Enrolled606ConditionsAlopecia AreataArmsBaricitinib, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Brett KingDepartment of Dermatology, Yale School of Medicine, New Haven, CT, USA.
Maryanne SennaLahey Dermatology, Burlington, MA, USA.
Manabu OhyamaDepartment of Dermatology, Kyorin University School of Medicine, Tokyo, Japan.
Rodney SinclairSinclair Dermatology, Melbourne, Australia.
Najwa SomaniEli Lilly and Company, Indianapolis, USA.
Na LuPrecision Statistics Consulting, Woodbury, USA.
Yun-Fei ChenEli Lilly and Company, Indianapolis, USA.
Jakub JedynakEli Lilly and Company, Indianapolis, USA.
Andrew BuchananEli Lilly and Company, Indianapolis, USA.
Bianca Maria PiracciniPrivate Dermatology Practice, Bologna, Italy. drpiraccini25@gmail.com.ORCID http://orcid.org/0000-0001-6537-9689

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionScalp hair regrowth in severe alopecia areata (AA) can occur rapidly or take up to 2 years in some patients. Baseline factors influence the likelihood and/or timing of treatment response with Janus kinase inhibitors. We evaluated initial evidence of improvement (Severity of Alopecia Tool

methodsIn a post hoc analysis of BRAVE-AA1/2 (NCT03570749/NCT03899259), baricitinib 4 mg treatment subgroups were assessed for SALT

resultsIn severe AA (SALT score 50-94), SALT

conclusionsSevere subgroups usually achieve SALT

Indexed as

Alopecia areataBaricitinibSeverity of alopecia tool

Identifiers

PMID41989657
PMCPMC13237310

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.